Evommune, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
EVMN$7.84+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Six Months Ended | ||||
|---|---|---|---|---|
| June 30, | ||||
| 2026 · 2025 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $ | (53,920) | $ | (28,122) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation expense | 8,052 | 1,100 | ||
| Net amortization of premiums and accretion of discounts on investments | (1,548) | (673) | ||
| Depreciation and amortization | 901 | 752 | ||
| Change in fair value of convertible preferred stock forward | — | (8,928) | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other assets | 858 | (5,416) | ||
| Accounts payable | (2,766) | (4,591) | ||
| Accrued liabilities | 1,141 | (813) | ||
| Operating lease liabilities | (537) | (416) | ||
| Deferred revenue | — | (3,000) | ||
| Net cash used in operating activities | (47,819) | (50,107) | ||
| Cash flows from investing activities: | ||||
| Purchases of investments | (126,416) | — | ||
| Maturities of investments | 72,617 | 31,500 | ||
| Purchase of property and equipment | (266) | — | ||
| Net cash (used in) provided by investing activities | (54,065) | 31,500 | ||
| Cash flows from financing activities: | ||||
| Proceeds from private placement financing, net of transaction costs | 117,140 | — | ||
| Proceeds from issuance of convertible preferred stock, net of issuance costs | — | 65,228 | ||
| Proceeds from exercise of stock options | 732 | 6 | ||
| Payment of deferred offering costs | — | (736) | ||
| Principal payments of finance lease liability | (229) | (192) | ||
| Principal payments of financing obligation | — | (117) | ||
| Net cash provided by financing activities | 117,643 | 64,189 | ||
| Net increase in cash, cash equivalents and restricted cash | 15,759 | 45,582 | ||
| Cash, cash equivalents and restricted cash, beginning of period | 45,478 | 16,463 | ||
| Cash, cash equivalents and restricted cash, end of period | $ | 61,237 | $ | 62,045 |
| Components of cash, cash equivalents, and restricted cash | ||||
| Cash and cash equivalents | 60,034 | 61,837 | ||
| Restricted cash | 1,203 | 208 | ||
| Total cash, cash equivalents, and restricted cash | 61,237 | 62,045 | ||
| Supplemental cash flow disclosures: | ||||
| Cash paid for interest | $ | 4 | $ | 7 |
| Deferred offering costs in accrued expenses | — | 583 | ||
| Non-cash investing and financing activities: | ||||
| Unpaid fixed asset purchases | 54 | — | ||
| Vesting of early exercised stock options | 16 | 20 | ||
| Operating lease liabilities arising from obtaining right-of-use assets | 6,682 | — | ||
| Assets acquired under finance leases | 652 | — | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.